# Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

> **NCT02688270** · PHASE2 · COMPLETED · sponsor: **Covis Pharma S.à.r.l.** · enrollment: 65 (actual)

## Conditions studied

- Raynaud's Phenomenon Secondary to Connective Tissue Disease

## Interventions

- **DRUG:** Vascana (0.9% nitroglycerin cream)
- **DRUG:** Vehicle Cream (placebo)

## Key facts

- **NCT ID:** NCT02688270
- **Lead sponsor:** Covis Pharma S.à.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2022-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688270, "Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02688270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*